Published in Blood on September 27, 2012
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell (2013) 1.88
KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget (2015) 0.98
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica (2013) 0.89
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia (2016) 0.86
The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma. J Biol Chem (2015) 0.85
Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. J Cancer (2014) 0.85
Transcriptome profiling reveals differentially expressed transcripts between the human adrenal zona fasciculata and zona reticularis. J Clin Endocrinol Metab (2013) 0.81
Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol (2014) 0.81
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib). Mol Pharmacol (2014) 0.80
Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy. J Biol Chem (2014) 0.79
The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. Oncotarget (2014) 0.79
PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancer. PLoS One (2013) 0.78
Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis. Cell Res (2014) 0.78
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica (2015) 0.77
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol (2016) 0.75
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A (2016) 0.75
Salvage therapy of multiple myeloma: the new generation drugs. Biomed Res Int (2014) 0.75
Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol (2017) 0.75
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proc Natl Acad Sci U S A (2016) 0.75
A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress. BMC Cancer (2017) 0.75
Controlling the false discovery rate in behavior genetics research. Behav Brain Res (2001) 21.82
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
The proteasome: paradigm of a self-compartmentalizing protease. Cell (1998) 8.43
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol (2006) 4.01
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure (2006) 2.56
Proteasome inhibition measurements: clinical application. Clin Chem (2000) 2.04
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78
Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem Biol (1999) 1.65
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia (2010) 1.64
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med (2008) 1.40
Proteasome system of protein degradation and processing. Biochemistry (Mosc) (2009) 1.35
Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther (2008) 1.30
Molecular structure of 20S and 26S proteasomes. Enzyme Protein (1993) 1.21
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia (2006) 1.13
Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One (2011) 1.10
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol (2009) 1.08
Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res (2008) 1.02
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther (2012) 1.02
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma (2009) 1.00
Studies on the yeast proteasome uncover its basic structural features and multiple in vivo functions. Enzyme Protein (1993) 0.97
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med (2003) 4.90
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Multiple myeloma. Lancet (2009) 4.60
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol (2009) 3.19
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell (2011) 3.12
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07